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 Erythropoiesis-stimulating agents (ESAs) 
have now been used for about three dec-
ades in chronic kidney disease (CKD) 
patients to treat the symptoms of anemia, 
avoid potentially hazardous blood-prod-
uct transfusions, improve some facets of 
quality of life, and (with less certainty) 
reduce cardiovascular risk. 1 Initial re-
ports of the use of ESAs in patients with 
low(er) hemoglobin levels focused on 
dramatic short-term improvements in 
a plethora of surrogate end points but 
regrettably did not then attempt to focus 
on harder, longer-term outcomes such as 
overall patient survival. For more than 
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 Significant further evidence 
to bolster the link between 
epoetin and strokes in chronic 
kidney disease and cancer 
 David J.  Goldsmith 1 and  Adrian C.  Covic 2 
 Erythropoiesis-stimulating agents (ESAs) have been used for about 
three decades in chronic kidney disease patients to treat the symptoms 
of anemia, avoid potentially hazardous blood-product transfusions, 
improve some facets of quality of life, and reduce cardiovascular risk. 
We review a new article in which this association between stroke and 
ESA use is examined in a different population in a different way, 
but with the same worrying findings as seen in the TREAT study. 
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20 years there was only one direction of 
travel — more ESA use, and higher mean 
hemoglobin levels, 2 fueled by a poor 
evidence base, rather more rigid guide-
line statements than could be justifi ed, 
and a naive faith that in the treatment of 
hemoglobin levels rather than patients, 
good things would happen. 3 Th is was 
augmented by repetitive practice-pattern 
surveys equating higher achieved hemo-
globin levels with better care of patients. 
Th e fact that a patient lies within a guide-
line range, or above or below a guideline 
target, does not mandate better patient-
level outcomes. 
 However, from 2006 – 2007 there were 
ominous warning signs of trouble ahead; 
and it is interesting to see now in retro-
spect how the Correction of Hemoglobin 
and Outcomes in Renal Insufficiency 
(CHOIR) and Cardiovascular Risk Reduc-
tion by Early Anemia Treatment with 
Epoetin Beta (CREATE) publications of 
2006 — showcasing increases in cardiovas-
cular and renal end points, respectively —
 did then quickly lead to a marked 
reduction in ESA usage, ESA dosage, and 
thus achieved hemoglobin levels. 4 Th is 
 ‘ reverse trend ’ was given further momen-
tum by the Trial to Reduce Cardiovascular 
Events With Aranesp Th erapy (TREAT) 
study, published in 2009, which rand-
omized diabetic CKD patients to darbe-
poetin, dosed to maintain hemoglobin of 
13  g / dl, versus placebo / control with lim-
ited darbepoetin therapy, to maintain 
hemoglobin     9  g / dl (for a good review 
of this trial, see Goldsmith and Covic 5 ). 
One of the most alarming outcomes from 
TREAT was the finding that patients 
assigned to active darbepoetin treatment 
had double the risk of stroke when com-
pared with those receiving placebo (153 
total events, 5.0 % versus 2.6 % ). It was now 
clearer than ever, to anyone who was lis-
tening, that the use of ESAs was a fi nely 
nuanced intervention — there was no sur-
vival advantage at all to maintaining a 
significantly higher hemoglobin level, 
while there were excesses of strokes, and 
cancer (only in those with a previous his-
tory of cancer), in the more intensive arm 
of the TREAT study. Most importantly, 
that meant that, overall, the hard end-
point outcomes of a low-intensity, ESA-
light, approach were identical to those of 
a higher-intensity, and expensive, ESA-
reliant approach. 5 
 We need now to remember, though, that 
by the time TREAT was published in 2009, 
the use of ESAs had spread far beyond its 
beginnings in CKD patients to diverse clin-
ical areas such as myelodysplasia, anemia of 
chronic disease,  ‘ heart failure, ’ and cancer-
induced, or chemotherapy-induced, 
anemia. 1 In particular, the use of high-
dose ESA therapy to  ‘ rescue ’ chemother-
apy-induced anemia had become 
signifi cantly more common. 6 Evidence for 
benefi t was, as in the early days of ESA use 
in CKD, confi ned to modest changes in 
quality of life and shorter-term surrogate 
end points. Furthermore, in the rush to 
establish ESAs as standard of care in this 
and other conditions, people discounted 
the possibility that diff erent cancers, and 
diff erent chemotherapy regimens, might 
interact adversely with the use of ESAs. 
Subsequently, excess morbidity and mor-
tality began to be reported in cancer 
patients treated with ESAs. 6 
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 Seliger and colleagues of Maryland 7 
(this issue) now provide helpful addi-
tional information by testing whether the 
association between stroke and ESA use 
could be replicated in a different but 
more relevant patient setting, closer to 
 ‘ ambulatory care. ’ Th is was an observa-
tional nested case-control study con-
ducted to examine the relationship of 
ESA use to acute stroke in anemic non-
dialysis CKD patients, and among sub-
groups of patients with  comorbidities 
including diabetes and  cancer, using 
national data from the  Veterans Health 
Administration (VHA). 
 As this interesting paper is not another 
randomized controlled trial, we need to 
understand clearly the methodology so 
we can decide how much weight to put 
on the fi ndings. It is a nested, matched 
case-control study using administrative 
data collected by the VHA. Subjects were 
VHA patients with an initial outpatient 
MDRD estimated glomerular fi ltration 
rate less than 60 cc / min / 1.73  m 2 during 
one of three time periods from 2000 to 
2005 and a subsequent outpatient hemo-
globin level less than 12  g / dl. Among 
patients who met the criteria for esti-
mated glomerular filtration rate and 
hemoglobin, the authors identifi ed all 
those with an acute-care hospitalization 
for an acute stroke reported between the 
index anemia date and the last date of 
follow-up; these patients were defi ned as 
stroke cases. Acute stroke was ascer-
tained by an ICD-9 discharge diagnosis-
coding algorithm that had been validated 
as highly accurate for the ascertainment 
of stroke cases, and included both 
ischemic and hemorrhagic strokes. Con-
trols were selected among those patients 
who did not experience an acute stroke 
hospitalization between the index ane-
mia date and the end of follow-up. Each 
case was matched to fi ve control patients 
on the basis of the patients ’ total dura-
tion of observation aft er incident anemia 
( ± 60 days). 
 Patient characteristics that might relate 
to stroke and ESA use were compared 
between stroke cases and controls by 
appropriate statistical methods. Condi-
tional logistic regression was used to esti-
mate the association of ESA use with 
stroke-case status, while controlling for 
potential confounders. A hierarchical 
modeling approach was used, adjusting 
for sets of progressively more complete 
confounders. In the primary analysis, ESA 
use was considered as a binary variable 
(treated versus untreated), but in second-
ary analyses, it was possible to probe 
dose – response relationships by compar-
ing those with initial high or low doses 
with untreated patients. Interactions 
between ESA use and diabetes, cancer, 
prior cerebrovascular disease, atrial 
 fi brillation, coronary artery disease, and 
recent nephrology care, with the use of 
multiplicative interaction terms, were also 
tested for. 7 
 Th e main fi ndings of this study are that 
among a large national case-control 
 sample of CKD patients with anemia, 
those treated with ESAs had a concerning 
30 % greater risk of stroke than patients 
who were not treated with ESAs, aft er 
adjustment for multiple confounding 
variables including demographics, 
comorbidity, severity and rate of progres-
sion of anemia, and health-care utiliza-
tion. The increased risk of stroke 
associated with ESA use was most pro-
nounced among patients with cancer. 7 
 So we now find that the alarming 
TREAT stroke fi ndings have been repli-
cated in a large, more heterogeneous 
clinical CKD population including non-
diabetics and patients with cancer, with 
over 2000 stroke events to consider. Th e 
CHOIR and CREATE trials, which 
random ized anemic CKD patients to 
high and low hemoglobin targets, did not 
find an excess risk of stroke with the 
higher hemoglobin target. However, the 
number of stroke events was very low in 
both these prior studies, neither of which 
had been specifi cally designed to exam-
ine stroke as the primary outcome. Cru-
cially also in our view, unlike TREAT, 
neither study had a  ‘ control ’ (or ESA-
light) arm to compare with more aggres-
sive ESA usage. 5 
 A notable fi nding is a signifi cant eff ect 
modifi cation by the presence of cancer, 
with an 83 % greater odds of stroke associ-
ated with ESA use among patients with 
cancer under active oncology care (at the 
 P  =  0.015 level). While data from several 
studies have shown that ESA use among 
patients with certain types of cancer is 
associated with an increased risk of mor-
tality and tumor progression or recur-
rence, 6 the study by Seliger  et al. 7 is the 
first to report an association of excess 
stroke risk with ESA use in CKD patients 
with cancer. Patients with active cancer 
were, of course, excluded from the 
TREAT and CHOIR studies, so this could 
not have come to light before. To investi-
gate further the reasons for this specifi c 
eff ect modifi cation, factors related to ane-
mia and ESA use that diff ered between 
those with and without cancer were 
examined; cancer patients were treated 
with much higher initial doses of ESAs 
than non-cancer patients (2.5 times 
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 Figure 1  |  Current ESA usage among cancer patients. In the United States, the use of 
erythropoiesis-stimulating agents (ESAs) to treat anemia in cancer patients has fallen to about 
half the rate in Europe, as shown in the graph. After 2007, drug labels in the United States warned 
that ESAs could increase the risk of cardiovascular disease and death, and Medicare and private 
insurers began to restrict coverage. In Europe and Canada, where safety warnings are less strong, 
usage did not decline markedly, according to a recent study by James Armitage of the University of 
Nebraska ’ s Eppley Cancer Center and other researchers. They conclude that  ‘ varying interpretations 
of risks and benefits of ESAs internationally are now apparent. ’ Source: Bennett  et al. 12 (Figure 
adapted with permission, Oxford University Press 2010, doi:10.1093 / jnci / djq492.) 
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greater for darbepoetin users and four 
times greater for epoetin users), although 
their severity of anemia prior to ESA ini-
tiation did not diff er. Of course, patients 
in this study were not typical of CKD 
patients, in that their anemia was clearly 
disproportionate to their loss of kidney 
function, implying that their cancer, or its 
treatment, was playing a larger part in its 
pathogenesis. 
 If we now try to draw together a few of 
the disparate strands of evidence, we feel 
that there is a consistent fi nding emerg-
ing from a large number of different 
studies, trials, observations, and com-
mentaries. Th is present publication by 
Seliger  et al. 7 supports the supposition 
that, in persisting in using large doses of 
ESAs in selected populations at greater 
vascular / occlusive risk, such as CKD, 
diabetes, and cancer, there is a special 
risk of adverse cardiovascular outcomes. 
Patients who respond well, and quickly, 
to low to modest doses of ESAs are at lit-
tle risk of adverse outcomes from this 
intervention; this type of patient tends to 
be less anemic at the outset and have 
fewer chronic debilitating comorbidities. 
However, more chronically challenged 
patients, oft en with more severe anemia 
 ab initio , are also more resistant to ane-
mia interventions, whatsoever they may 
be. It is in this type of patient where the 
biggest risk lies, and where large doses of 
ESA can be used in an oft en futile attempt 
to (over) drive profoundly dysfunctional 
erythropoiesis. 1,8 Dose-related ESA-
induced increases in blood viscosity, 
platelet numbers, platelet reactivity, 
blood pressure, and endothelial dysfunc-
tion might all be playing a part in throm-
botic complications such as stroke, 
myocardial infarction, and vascular 
access malfunction. 1 
 It is salutary to report, then, that in 
 cancer-associated anemia, 9 and also in 
more traditional CKD-associated  anemia, 4 
the extent of ESA use is now dropping 
signi fi cantly, which will more than likely 
at one and the same time reduce adverse 
clinical as well as fi nancial implications. 10 
Th is is shown in another way in  Figure 1 , 
in which the diff erent global approaches 
to the use of ESAs in cancer patients can 
clearly be seen. 11 Very much more 
research is now urgently needed in these 
domains, and perhaps, in view of infl u-
ences that can be detected in the fi ndings 
of publications varying with their funding 
source, funding for these studies should 
preferably come from fully independent 
sources. 9 Guideline groups such as Kidney 
Disease: Improving Global Outcomes 
(KDIGO; due to report again post-TREAT 
in 2011) now have a special and heavy 
responsibility to produce clinically rele-
vant and correct guidance that will avoid 
harm at all costs. 
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